Get the Stockscreener App
45.71
6.38%
2.74
After Hours:
45.70
-0.010
-0.02%
Korro Bio Inc stock is traded at $45.71, with a volume of 259.51K.
It is up +6.38% in the last 24 hours and up +48.60% over the past month.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
See More
Previous Close:
$42.97
Open:
$44.09
24h Volume:
259.51K
Relative Volume:
1.27
Market Cap:
$429.26M
Revenue:
-
Net Income/Loss:
$-81.17M
P/E Ratio:
-4.5104
EPS:
-10.1344
Net Cash Flow:
$-82.84M
1W Performance:
+4.60%
1M Performance:
+48.60%
6M Performance:
+254.34%
1Y Performance:
+18.21%
1-Day Range:
$42.05
$47.55
1-Week Range:
$40.70
$50.64
52-Week Range:
$10.29
$98.00
Korro Bio Inc Stock (KRRO) Company Profile
Name
Korro Bio Inc
Sector
Industry
Phone
617-468-1999
Address
60 FIRST STREET, CAMBRIDGE
Compare KRRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
45.71 | 403.53M | 0 | -81.17M | -82.84M | -10.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-16-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Raymond James | Strong Buy |
| Aug-14-24 | Initiated | William Blair | Outperform |
| Mar-28-24 | Reiterated | H.C. Wainwright | Buy |
| Feb-27-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-04-23 | Initiated | H.C. Wainwright | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-13-23 | Downgrade | Cowen | Outperform → Market Perform |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jan-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-28-19 | Initiated | Cowen | Outperform |
| Oct-28-19 | Initiated | Goldman | Buy |
| Oct-28-19 | Initiated | JP Morgan | Overweight |
View All
Korro Bio Inc Stock (KRRO) Latest News
Tools to assess Korro Bio Inc.’s risk profileWeekly Profit Analysis & Stock Portfolio Risk Management - newser.com
Analyzing recovery setups for Korro Bio Inc. investorsDollar Strength & Short-Term Trading Alerts - newser.com
Is Korro Bio Inc. stock positioned for long term growthAnalyst Downgrade & Community Verified Watchlist Alerts - newser.com
Risk vs reward if holding onto Korro Bio Inc.Earnings Summary Report & AI Driven Stock Movement Reports - newser.com
Short interest data insights for Korro Bio Inc.2025 Fundamental Recap & Daily Technical Forecast Reports - newser.com
Using economic indicators to assess Korro Bio Inc. potential2025 Valuation Update & Fast Exit Strategy with Risk Control - newser.com
Live market analysis of Korro Bio Inc.July 2025 Setups & Detailed Earnings Play Alerts - newser.com
Key metrics from Korro Bio Inc.’s quarterly dataJuly 2025 Momentum & Stepwise Entry/Exit Trade Alerts - newser.com
Has Korro Bio Inc. formed a bullish divergence2025 Earnings Impact & Community Verified Swing Trade Signals - newser.com
Using Python tools to backtest Korro Bio Inc. strategiesDip Buying & Advanced Swing Trade Entry Alerts - newser.com
Korro Bio CFO Vineet Agarwal Resigns, Interim Appointed - The Globe and Mail
Is a relief rally coming for Korro Bio Inc. holdersEarnings Growth Summary & Short-Term High Return Strategies - newser.com
Korro Bio, Inc. Announces Chief Financial Officer Changes, Effective October 17, 2025 - MarketScreener
Korro Bio CFO Vineet Agarwal to step down, CEO Ram Aiyar named interim CFO - Investing.com Canada
Korro BioVineet Agarwal announces intention to resign from his position of CFO - MarketScreener
What analysts say about Korro Bio Inc stockEarnings Growth Patterns & Free Double Digit Growth Tips - earlytimes.in
What drives Korro Bio Inc stock priceValue Traps to Avoid & Free High Yield Investment Strategies - earlytimes.in
Chart based analysis of Korro Bio Inc. trends2025 Bull vs Bear & Real-Time Volume Analysis - newser.com
Is Korro Bio Inc. stock reversal real or fake2025 Year in Review & Momentum Based Trading Ideas - newser.com
Korro Bio Inc. stock prediction for this weekWeekly Stock Analysis & Free Community Supported Trade Ideas - newser.com
When is the best time to exit Korro Bio Inc.Day Trade & AI Forecasted Entry/Exit Points - newser.com
Press Release: Korro Reports Full Year 2024 Financial Results and Provides Business Updates - 富途牛牛
Piper Sandler Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $180 - 富途牛牛
Applying sector rotation models to Korro Bio Inc.Market Growth Report & Safe Capital Growth Tips - newser.com
How to build a custom watchlist for Korro Bio Inc.2025 Investor Takeaways & Community Consensus Picks - newser.com
Korro Bio Inc. stock retracement – recovery analysisWeekly Trade Report & Community Shared Stock Ideas - newser.com
Korro Bio Inc Stock (KRRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Korro Bio Inc Stock (KRRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Agarwal Vineet | Chief Financial Officer |
Nov 11 '24 |
Sale |
70.00 |
800 |
56,000 |
0 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):